

3/ 20. (Amended) An immunogenic composition according to claim ~~61~~^{or claim 62}, wherein the immunostimulant induces a predominantly Type I response.

4/ 22. (Amended) A method for stimulating an immune response in a patient, comprising administering to a patient an effective amount of an immunogenic composition according to claim ~~61~~^{or claim 62} ~~6~~

26. (Amended) An immunogenic composition according to claim 64, wherein the immunostimulant is an adjuvant.

27. (Amended) An immunogenic composition according to claim 64, wherein the immunostimulant induces a predominantly Type I response.

28. (Amended) An immunogenic composition according to claim 64, wherein the antigen-presenting cell is a dendritic cell.

C1 cancelled
30. (Amended) A method according to claim 65, wherein the antigen-presenting cell is a dendritic cell.

Please add new claims 61-65 to read as follows:

Sub D1
C2
61. (New) An immunogenic composition comprising an immunostimulant and a polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of:

- (a) SEQ ID NO: 113 and
- (b) immunogenic portions of SEQ ID NO: 113.

62. (New) An immunogenic composition comprising an immunostimulant and a polypeptide, wherein the polypeptide comprises a sequence having at least 90% identity to

SEQ ID NO: 113 and possesses an ability to stimulate a cytotoxic T lymphocyte response in sera from normal donors.

5 ~~63~~. (New) An immunogenic composition according to claim ~~61~~^{1. or claim 62} wherein the immunostimulant is selected from the group consisting of: monophosphoryl lipid A; 3-de-O-acylated monophosphoryl lipid A; and saponins.

Sub D2 64. (New) An immunogenic composition comprising an immunostimulant and an antigen-presenting cell that expresses a polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of:

- (a) SEQ ID NO: 113;
- (b) immunogenic portions of SEQ ID NO: 113; and
- (c) sequences having at least 90% identity to SEQ ID NO: 113, wherein the polypeptide possesses an ability to stimulate a cytotoxic T lymphocyte response in sera from normal donors.

62 could 8 ~~65~~. A method for stimulating an immune response in a patient, comprising administering a composition according to claim ~~64~~⁷.

REMARKS

The pending claims have been amended to remove reference to non-elected subject matter. Specifically, claim 18 has been rewritten as newly added claim 61. Newly added claim 62 is drawn to compositions comprising polypeptides that comprise a sequence having at least 90% identity to elected SEQ ID NO: 113 and possess an ability to stimulate a cytotoxic T lymphocyte response in sera from normal donors. It is submitted that support for newly added claim 62 may be found on page 81, line 24 – page 82, line 12, and in Example 9 (page 147, line 16 – page 148, line 8) of the specification as originally filed. Newly added claim 63, dependent upon claim 61, is drawn to immunogenic compositions comprising an immunostimulant selected from the group consisting of monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, and saponins. Support for claim 63 may be found on page 106, lines 13-29, and throughout the